- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04186858
Assessment of Levels of Intracellular Cytokines and Markers in Cells Recovered From the Anterior Eye (Phase 4)
31. januar 2020 oppdatert av: Johnson & Johnson Vision Care, Inc.
This is a single-visit, non-randomized, bilateral, cross-sectional study.
In a pre-screening assessment, potential subjects will be invited to complete a web-based questionnaire that is validated to determine symptomatic vs asymptomatic contact lens wearers.
Results of this questionnaire will be used to determine whether subjects are eligible to proceed to Visit 1.
During Visit 1, cell samples will be collected from the front surface of the subject's eyes.
Studieoversikt
Status
Fullført
Forhold
Studietype
Observasjonsmessig
Registrering (Faktiske)
22
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Manchester, Storbritannia
- Eurolens Research - The University of Manchester
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 45 år (Voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Eligible subjects aged 18 years and above with normal healthy eyes will be recruited for this work.
Beskrivelse
Inclusion Criteria:
Potential subjects must satisfy all of the following criteria to be enrolled in the study:
- The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form
- Appear able and willing to adhere to the instructions set forth in this clinical protocol.
- Be between 18 and 45 years of age (inclusive) at the time of screening
- They have worn the same brand of soft contact lenses for at least the previous three months.
- They agree not to participate in other clinical research trials for the duration of this study.
- In a pre-study screening assessment, they must have a CLDEQ-8 score of 10 or less (asymptomatic group) or 20 or higher (symptomatic group).
- They possess a wearable pair of distance glasses and agree to bring these to the study visit (if needed for distance vision correction).
- They can attain a high contrast logMAR visual acuity of 0.20 or better in their habitual contact lenses.
Their habitual contact lenses fit satisfactorily.
Exclusion Criteria:
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- Currently pregnant or lactating
- Any systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with contact lens wear and/or participation in the study
- They have an ocular disorder which would normally contraindicate contact lens wear.
- They have had cataract surgery.
- They have had corneal refractive surgery.
- They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus.
- They have taken part in any other contact lens or care solution clinical trial research, within two weeks prior to starting this study.
- They are regularly (once per day or more) using oral or inhaled steroids or anti-inflammatory medications.
- They are using any topical medications such as eye drops or ointments.
- History of allergic reaction to sodium fluorescein or topical anesthetic.
- Use of systemic medications (e.g., chronic steroid use) that are known to interfere with contact lens wear
- Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
- They have Grade 3 or greater of any of the following ocular surface signs: corneal edema, corneal vascularization, corneal staining (white light evaluation), tarsal conjunctival changes or any other abnormality which would normally contraindicate contact lens wear.
- Any active ocular infection or inflammation.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Symptomatic
Based on the score of the questionnaire, eligible subjects will be placed in the Symptomatic group where cell samples will be collected from the front surface of the subject's eyes.
|
|
Asymptomatic
Based on the score of the questionnaire, eligible subjects will be placed in the Asymptomatic group where cell samples will be collected from the front surface of the subject's eyes.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Cells
Tidsramme: ~6 hours of contact lens wear time
|
The frequency count of cells will be summarized within the category
|
~6 hours of contact lens wear time
|
|
Types of Cells
Tidsramme: ~6 hours of contact lens wear time
|
The percentage of types of cells will be summarized within the category.
|
~6 hours of contact lens wear time
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
12. november 2019
Primær fullføring (Faktiske)
9. januar 2020
Studiet fullført (Faktiske)
9. januar 2020
Datoer for studieregistrering
Først innsendt
3. desember 2019
Først innsendt som oppfylte QC-kriteriene
3. desember 2019
Først lagt ut (Faktiske)
5. desember 2019
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
5. februar 2020
Siste oppdatering sendt inn som oppfylte QC-kriteriene
31. januar 2020
Sist bekreftet
1. januar 2020
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- CR-6316
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
JA
IPD-delingstidsramme
Johnson & Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health.
Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .